Health Canada Approves Ocaliva for Autoimmune Liver Disease Patients
Canadian patients with the autoimmune liver disease primary biliary cholangitis (PBC) saw the first approval of a new drug for their condition in more than…
News
SIR-Spheres Radiation Therapy Increases Chance Liver Cancer Can Be Operated on, Study Reports
Those with liver cancer that has spread from the colon have a better chance of surgical removal of their liver tumors after treatment with…
Change in Intestinal Fungus Mix May Contribute to Alcoholic Liver Disease, Study Reports
Alcohol alters the intestines’ fungus mix, and the imbalance may contribute to the development and progression of alcoholic liver disease (ALD), a study reports. Researchers…
Organovo’s 3D Bioprinted Tissue Transplants Improve Mice’s Liver Disease
Transplanting 3D bioprinted liver tissue into diseased livers improves liver health in mice, Organovo Holdings revealed. The finding suggests that doctors could use 3D bioprinted…
Intercept Receives NORD Innovation Award for Ocaliva Therapy to Treat Rare Liver Disease
The National Organization for Rare Disorders (NORD) gave its 2017 Industry Innovation Award to Intercept Pharmaceuticals for the company’s primary biliary cholangitis (PBC) drug …
Albireo Plans Phase 3 Trial of A4250 to Treat Children with Life-threatening Liver Disease
Children with progressive familial intrahepatic cholestasis will be able to take part in a Phase 3 clinical trial of A4250’s ability to combat the rare genetic…
Blocking 2 Types of Immune Cells Seen to Prevent NASH in Mice, Raising Hope of Treatment
Nonalcoholic steatohepatitis, or NASH, might be prevented by treatments able to target certain immune cells, according to a recent study in mice which demonstrated that the condition has…
Albireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…
Monkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in…
New Data Highlights Advantages of Accuray’s CyberKnife for Treating Liver Metastasis
Researchers presented more than 50 studies highlighting the benefits of Accuray’s CyberKnife System at the 36th Annual European Society for Radiotherapy and Oncology (ESTRO)…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say